| Dr Sarah Lynn Salce, DNP | |
|
2000 S Thompson St, Flagstaff, AZ 86001-8759 | |
| (928) 226-6400 | |
| (928) 226-6401 |
| Full Name | Dr Sarah Lynn Salce |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 2000 S Thompson St, Flagstaff, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003337981 | NPI | - | NPPES |
| 1003337981 | Medicaid | WA | |
| 8968757 | Other | WA | MEDICARE PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | 60776635 (Washington) | Secondary |
| 363LA2100X | Nurse Practitioner - Acute Care | 219445 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Flagstaff Medical Center | Flagstaff, AZ | Hospital |
| Verde Valley Medical Center | Cottonwood, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northern Arizona Healthcare Corporation | 3577473362 | 370 |
News Archive
In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.
New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. According to scientists at Duke University Medical Center, this suggests the window of opportunity for successful intervention may be only a matter of days - not weeks - after transmission, as researchers had previously believed.
Women's Health Weekly recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.
Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy, compared to surgery - this is the finding of a new study conducted by PANAXEA, The University of Twente, Netherlands.
› Verified 8 days ago
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.
New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. According to scientists at Duke University Medical Center, this suggests the window of opportunity for successful intervention may be only a matter of days - not weeks - after transmission, as researchers had previously believed.
Women's Health Weekly recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.
Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy, compared to surgery - this is the finding of a new study conducted by PANAXEA, The University of Twente, Netherlands.
› Verified 8 days ago
| Entity Name | Northern Arizona Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669914552 PECOS PAC ID: 3577473362 Enrollment ID: O20170801003409 |
News Archive
In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.
New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. According to scientists at Duke University Medical Center, this suggests the window of opportunity for successful intervention may be only a matter of days - not weeks - after transmission, as researchers had previously believed.
Women's Health Weekly recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.
Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy, compared to surgery - this is the finding of a new study conducted by PANAXEA, The University of Twente, Netherlands.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sarah Lynn Salce, DNP 1200 N Beaver St, Flagstaff, AZ 86001-3118 Ph: (928) 213-6235 | Dr Sarah Lynn Salce, DNP 2000 S Thompson St, Flagstaff, AZ 86001-8759 Ph: (928) 226-6400 |
News Archive
In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.
New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood. According to scientists at Duke University Medical Center, this suggests the window of opportunity for successful intervention may be only a matter of days - not weeks - after transmission, as researchers had previously believed.
Women's Health Weekly recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.
Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy, compared to surgery - this is the finding of a new study conducted by PANAXEA, The University of Twente, Netherlands.
› Verified 8 days ago
Wyatt D Woodard, MSN, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 320 N Leroux St, Ste B, Flagstaff, AZ 86001 Phone: 928-779-0361 Fax: 928-779-7143 | |
Mr. Richard R Valdes, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2920 N 4th St, Flagstaff, AZ 86004 Phone: 928-213-6100 Fax: 928-774-4808 | |
Ms. Sherry Ann Mace, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 77 W Forest Ave, Suite 301, Flagstaff, AZ 86001 Phone: 928-773-2538 | |
Ms. Julie Marie Polzin, RN, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 107 E Oak Ave, Suite 201, Flagstaff, AZ 86001 Phone: 928-913-8800 Fax: 928-913-8801 | |
Dr. Evenstar Amelia Forbach, DNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 7510 W Bridle Trl, Flagstaff, AZ 86001 Phone: 928-600-1731 | |
Ms. Sarah Mcnaughton Preston, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1424 N Evergreen Dr, Flagstaff, AZ 86001 Phone: 928-699-9777 |